Sandra De Meyer

6.0k total citations
115 papers, 3.3k citations indexed

About

Sandra De Meyer is a scholar working on Infectious Diseases, Hepatology and Epidemiology. According to data from OpenAlex, Sandra De Meyer has authored 115 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Infectious Diseases, 61 papers in Hepatology and 46 papers in Epidemiology. Recurrent topics in Sandra De Meyer's work include Hepatitis C virus research (61 papers), HIV/AIDS drug development and treatment (58 papers) and Hepatitis B Virus Studies (31 papers). Sandra De Meyer is often cited by papers focused on Hepatitis C virus research (61 papers), HIV/AIDS drug development and treatment (58 papers) and Hepatitis B Virus Studies (31 papers). Sandra De Meyer collaborates with scholars based in United States, Belgium and Germany. Sandra De Meyer's co-authors include Gastón Picchio, Marie‐Pierre de Béthune, Tony Vangeneugden, Hilde Azijn, Éric Lefebvre, Dominique Surleraux, Rudi Pauwels, Piet Wigerinck, Abdellah Tahri and Dirk Jochmans and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Sandra De Meyer

111 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra De Meyer United States	32	1.9k	1.3k	1.2k	1.1k	356	115	3.3k
Miklos Salgo United States	22	2.1k 1.1×	539 0.4×	238 0.2×	1.9k 1.7×	469 1.3×	53	3.2k
Jay A. Grobler United States	30	2.6k 1.4×	750 0.6×	372 0.3×	1.9k 1.7×	1.4k 3.8×	61	3.7k
Rob Striker United States	26	599 0.3×	563 0.4×	340 0.3×	181 0.2×	721 2.0×	66	2.3k
R V Srinivas United States	25	1.0k 0.6×	568 0.4×	118 0.1×	911 0.8×	729 2.0×	58	2.4k
Luis Menéndez‐Arias Spain	38	2.4k 1.3×	683 0.5×	310 0.2×	2.1k 1.9×	1.9k 5.2×	143	4.6k
Georgios Pollakis Netherlands	29	1.1k 0.6×	785 0.6×	101 0.1×	1.7k 1.5×	685 1.9×	95	2.9k
Clyde S. Crumpacker United States	44	1.6k 0.9×	3.4k 2.5×	262 0.2×	1.6k 1.4×	961 2.7×	115	5.9k
Eleftherios Michailidis United States	24	1.2k 0.6×	726 0.6×	388 0.3×	531 0.5×	691 1.9×	46	2.1k
Wasun Chantratita Thailand	25	861 0.5×	726 0.6×	305 0.2×	572 0.5×	379 1.1×	156	2.6k
Horacio Salomón Argentina	31	2.3k 1.2×	893 0.7×	278 0.2×	2.4k 2.2×	525 1.5×	128	3.5k

Countries citing papers authored by Sandra De Meyer

Since Specialization

Citations

This map shows the geographic impact of Sandra De Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra De Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra De Meyer more than expected).

Fields of papers citing papers by Sandra De Meyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra De Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra De Meyer. The network helps show where Sandra De Meyer may publish in the future.

Co-authorship network of co-authors of Sandra De Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra De Meyer. A scholar is included among the top collaborators of Sandra De Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra De Meyer. Sandra De Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bömmel, Florian van, Thierry Verbinnen, Kosh Agarwal, et al.. (2025). Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.. PubMed. 9(3).

Thys, Kim, Matthew J. Loza, Katleen Callewaert, et al.. (2024). Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab. Scientific Reports. 14(1). 22981–22981.

Gottlieb, Robert, Meredith E. Clement, Paul Cook, et al.. (2024). The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19. Journal of Infection. 89(4). 106241–106241. 2 indexed citations

Verbinnen, Thierry, Willem Talloen, Harry L.A. Janssen, et al.. (2023). Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study. Antiviral Research. 216. 105660–105660. 4 indexed citations

Chiu, Winston, Christel Van den Eynde, Christophe Buyck, et al.. (2022). Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures. Journal of Medical Virology. 94(7). 3101–3111. 12 indexed citations

Verbinnen, Thierry, Willem Talloen, Jan Martin Berke, et al.. (2020). Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy. Journal of Viral Hepatitis. 27(11). 1127–1137. 14 indexed citations

Meyer, Sandra De, Denisa Bojková, Jindřich Činátl, et al.. (2020). Lack of antiviral activity of darunavir against SARS-CoV-2. International Journal of Infectious Diseases. 97. 7–10. 95 indexed citations

Lathouwers, Erkki, Soumi Gupta, Mojgan Haddad, et al.. (2015). Trends in Darunavir Resistance-Associated Mutations and Phenotypic Resistance in Commercially Tested United States Clinical Samples Between 2006 and 2012. AIDS Research and Human Retroviruses. 31(6). 628–635. 7 indexed citations

Berg, Thomas, Pietro Andreoné, Stanislas Pol, et al.. (2014). Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study. Liver International. 35(2). 448–454. 5 indexed citations

10.

Picchio, Gastón, Sandra De Meyer, Inge Dierynck, et al.. (2014). Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. Journal of Clinical Virology. 59(3). 148–155. 1 indexed citations

11.

Sarrazin, C., H.W. Reesink, Stefan Zeuzem, et al.. (2013). 898 TREATMENT WITH TELAPREVIR/PEG-IFN/RBV AFTER 14-DAY TELAPREVIR EXPOSURE IN PHASE I STUDIES: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY. Journal of Hepatology. 58. S369–S370. 3 indexed citations

12.

Agarwal, Kosh, Yves Horsmans, William Sievert, et al.. (2013). 798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY. Journal of Hepatology. 58. S326–S326. 6 indexed citations

13.

Sullivan, James C., Sandra De Meyer, Doug J. Bartels, et al.. (2013). Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. Clinical Infectious Diseases. 57(2). 221–229. 114 indexed citations

14.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION. Journal of Hepatology. 54. S3–S4. 21 indexed citations

15.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results: Abstract OP03 Table 1. Gut. 60(Suppl 2). A50.3–A51. 5 indexed citations

16.

Meyer, Sandra De, et al.. (2010). 251 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF GENOTYPE 2/3 HCV VARIANTS IN PATIENTS TREATED WITH TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN STUDY C209. Journal of Hepatology. 52. S106–S106. 1 indexed citations

17.

Vingerhoets, Johan, Hilde Azijn, Lotke Tambuyzer, et al.. (2010). Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data. AIDS Research and Human Retroviruses. 26(6). 621–624. 11 indexed citations

18.

Paulus, Ursula, Sandra De Meyer, Beate Pfistner, et al.. (2008). Systematic review about data quality and protocol compliance in clinical trials. SHILAP Revista de lepidopterología. 2 indexed citations

19.

Meyer, Sandra De, Tony Vangeneugden, Ben Van Baelen, et al.. (2008). Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials. AIDS Research and Human Retroviruses. 24(3). 379–388. 121 indexed citations

20.

Mayer, Konstantin, Sandra De Meyer, Ulrich A. Maus, et al.. (2003). Short-Time Infusion of Fish Oil-Based Lipid Emulsions, Approved for Parenteral Nutrition, Reduces Monocyte Proinflammatory Cytokine Generation and Adhesive Interaction with Endothelium in Humans. The Journal of Immunology. 171(9). 4837–4843. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact